BR0208275A - Composições farmacêuticas para tratamento de arteriosclerose - Google Patents

Composições farmacêuticas para tratamento de arteriosclerose

Info

Publication number
BR0208275A
BR0208275A BR0208275-6A BR0208275A BR0208275A BR 0208275 A BR0208275 A BR 0208275A BR 0208275 A BR0208275 A BR 0208275A BR 0208275 A BR0208275 A BR 0208275A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
treating atherosclerosis
treating
group
arteriosclerosis
Prior art date
Application number
BR0208275-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Akihiko Saiga
Takashi Ono
Katsutoshi Yamada
Kohji Hanasaki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BR0208275A publication Critical patent/BR0208275A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR0208275-6A 2001-03-19 2002-03-19 Composições farmacêuticas para tratamento de arteriosclerose BR0208275A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001078569 2001-03-19
JP2001401289 2001-12-28
PCT/JP2002/002585 WO2002074342A1 (fr) 2001-03-19 2002-03-19 Remedes contre l'arteriosclerose

Publications (1)

Publication Number Publication Date
BR0208275A true BR0208275A (pt) 2004-04-13

Family

ID=26611547

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208275-6A BR0208275A (pt) 2001-03-19 2002-03-19 Composições farmacêuticas para tratamento de arteriosclerose

Country Status (14)

Country Link
US (1) US20040248898A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2044958A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4499361B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100908968B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1553814B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE428425T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0208275A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2441110C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60231969D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2324766T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA03008440A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1378246E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI314457B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2002074342A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026318B2 (en) * 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
DE602005026553D1 (de) 2004-10-12 2011-04-07 Decode Genetics Ehf Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
SI1852433T1 (sl) 2004-10-29 2012-06-29 Zeria Pharm Co Ltd Derivat karbazola, njegov solvat ali njegova farmacevtsko sprejemljiva sol
CA2627043A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
AU2006311761A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having C4-amide substituents and use thereof as phospholipase-A2 inhibitors
CN101490045A (zh) 2006-05-16 2009-07-22 解码遗传Ehf公司 7-(丙烯酰基)吲哚的制备方法
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
AU2008247451A1 (en) * 2007-05-03 2008-11-13 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US20090062369A1 (en) * 2007-08-31 2009-03-05 Joaquim Trias Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
WO2010038104A1 (en) * 2008-10-03 2010-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event.
US20120093922A1 (en) 2009-04-29 2012-04-19 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101037404B1 (ko) * 2010-12-07 2011-05-30 박철형 가변설치가 가능한 압출본체에 의한 천장용 엘이디 조명등

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
EP0974663A1 (en) * 1993-06-25 2000-01-26 Smithkline Beecham Plc Lipoprotein associated phospholipase A2, inhibitors thereof and use of same in diagnosis and therapy
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
TW383302B (en) 1994-04-01 2000-03-01 Lilly Co Eli 1H-indole-3-glyoxylamide sPLA2 inhibitors
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
CN1158121A (zh) 1994-07-21 1997-08-27 伊莱利利公司 吲哚嗪sPLA2抑制剂
HUP9902120A3 (en) 1995-12-13 1999-12-28 Lilly Co Eli Naphthyl glyoxamides as spla2 inhibitors
IL124866A (en) 1995-12-13 2002-08-14 Lilly Co Eli Naphthalide acetamides as sPLA2 inhibitors
CA2269203A1 (en) 1996-10-30 1998-05-07 Nicholas James Bach Substituted tricyclics
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
AU3054399A (en) 1998-03-31 1999-10-25 Shionogi & Co., Ltd. Pyrrolo(1,2-a)pyrazine sPLA2 inhibitor
WO1999059999A1 (fr) * 1998-05-21 1999-11-25 Shionogi & Co., Ltd. DERIVES DE LA PYRROLO[1,2-B] PYRIDAZINE, A EFFET INHIBITEUR SUR LE sPLA¿2?
AU6004799A (en) * 1998-10-14 2000-05-01 Shionogi & Co., Ltd. Remedies or preventives for ischemic reflow failure
US6756376B1 (en) * 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
US7026318B2 (en) * 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect

Also Published As

Publication number Publication date
EP1378246A1 (en) 2004-01-07
JP4499361B2 (ja) 2010-07-07
CA2441110A1 (en) 2002-09-26
MXPA03008440A (es) 2004-01-29
CA2441110C (en) 2010-10-12
TWI314457B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-09-11
EP1378246A4 (en) 2004-07-07
KR100908968B1 (ko) 2009-07-22
EP2044958A3 (en) 2009-07-08
DE60231969D1 (de) 2009-05-28
ATE428425T1 (de) 2009-05-15
CN1553814B (zh) 2010-05-26
US20040248898A1 (en) 2004-12-09
CN1553814A (zh) 2004-12-08
KR20030085026A (ko) 2003-11-01
ES2324766T3 (es) 2009-08-14
WO2002074342A1 (fr) 2002-09-26
EP2044958A2 (en) 2009-04-08
JPWO2002074342A1 (ja) 2004-07-08
EP1378246B1 (en) 2009-04-15
PT1378246E (pt) 2009-05-22

Similar Documents

Publication Publication Date Title
BR0208275A (pt) Composições farmacêuticas para tratamento de arteriosclerose
DE69724777D1 (de) Pentafluorobenzensulfonamiden und analoge
BR0113989A (pt) Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
PT989851E (pt) Formulacao auto-emulsionante para compostos lipofilicos acidicos
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
EE200300329A (et) Meetod peroraalselt manustatavate epotiloonide biosaadavuse suurendamiseks ning selles kasutatav komplekt, ravimkoostis ja farmatseutiline ravimvorm
DK0639577T3 (da) Phosphonooxymethyl- eller methylthiomethylestere af taxanderivater som antitumormidler
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
NO20034011D0 (no) Steroider som agonister for FXR
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
ATE377010T1 (de) Caspase-inhibitoren und ihre verwendungen
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
SE0400043D0 (sv) New compounds
BRPI0513672A (pt) processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol
IT1312115B1 (it) Composti amorfi e relative composizioni farmaceutiche
NO995963D0 (no) Karboksamider anvendelige som 5-HTIF-agonister
DE60129442D1 (de) Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten
CY1106376T1 (el) Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
BR0210746A (pt) Derivados de 6-'2-(fosfonometóxi)alcóxi-pirimidina tendo atividade antiviral
BRPI0414186A (pt) compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto
BRPI0408423A (pt) composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
ES2189080T3 (es) Derivados de creatina para el asma.
DE69904519D1 (de) Sulfonamid-Derivate
BR9706360A (pt) Compostos de n-benzilpiperazina novos um processo para sua preparação e para as composições farmacêuticas que os contêm

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements